The FDA granted an appeal to an earlier decision, resetting tenapanor on a path toward approval for treating hyperphosphatemia in patients undergoing dialysis.
An FDA advisory committee said the benefits of tenapanor for treating hyperphosphatemia in patients on dialysis outweighed its risks as both mono- and combo-therapy.
RMJ Holdings Magnesium-based Drug Candidate RMJH-111B Data Presented at the American Heart Association's Hypertension 2021 Scientific Sessions prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.